1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Michael Luebbert: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) tranylcypromine, all-trans retinoic acid, cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Unknown | Michael Luebbert | 60 | 2015-05-01 | 2018-10-18 |
Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Recurrence (1)
Cytarabine (1) · Tranylcypromine (1) · Tretinoin (1)
Germany (1)